Edwyn
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | $42,518 | $46,385 | $46,159 | $45,006 | $48,300 |
| Gross Profit | $30,745 | $36,445 | $36,022 | $34,313 | $34,332 |
| Operating Income | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$9,015 | $6,994 | $6,327 | $8,025 | -$8,948 |
Over the past five years, Bristol-Myers Squibb’s revenue and gross profit figures have remained relatively stable, though they show some fluctuations that warrant attention. Revenue increased from US$42.5 billion in 2020 to US$46.4 billion in 2021 before declining slightly in 2022 and 2023, then rising again to US$48.3 billion in 2024. Gross profit followed a similar pattern, climbing from US$30.7 billion in 2020 to US$36.4 billion in 2021 and then gradually declining to around US$34.3 billion in 2023 and 2024. The consistency in these core figures suggests that the company’s fundamental operational performance—particularly in terms of production efficiency and cost management—has remained largely steady, despite minor shifts in overall revenue. A more pronounced volatility is evident in the net income figures. In 2020, the company recorded a net loss of approximately US$9.0 billion, which reversed to a positive US$7.0 billion in 2021—a swing exceeding 150% YoY improvement. This positive trend continued modestly into 2022 and peaked in 2023 at US$8.0 billion before taking a dramatic downturn to a US$8.9 billion loss in 2024. Given that operating income is consistently reported as zero, the swings in net income appear to be driven by non-operational items, such as extraordinary expenses, tax adjustments, or other one-off factors. Overall, while core revenue and gross margins remain robust, the sharp fluctuations in net income raise questions about the stability of other financial elements. This mixed performance suggests that while Bristol-Myers Squibb maintains a solid operational base, further scrutiny into its non-operational financial management is advisable to ensure long-term sustainability.
This analysis is for informational purposes only and does not constitute financial advice or recommendations for any investment decisions. Please consult with a qualified financial professional for personalized guidance.